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Integrated Survival Estimates for Cancer Treatment Delay
Among Adults With Cancer During the COVID-19 Pandemic
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IMPORTANCE Cancer treatment delay has been reported to variably impact cancer-specific
survival and coronavirus disease 2019 (COVID-19)–specific mortality during the severe acute
respiratory syndrome coronavirus 2 pandemic. During the pandemic, treatment delay is
being recommended in a nonquantitative, nonobjective, and nonpersonalized manner,
and this approach may be associated with suboptimal outcomes. Quantitative integration of
cancer mortality estimates and data on the consequences of treatment delay is needed to aid
treatment decisions and improve patient outcomes.
OBJECTIVE To obtain quantitative integration of cancer-specific and COVID-19–specific
mortality estimates that can be used to make optimal decisions for individual patients
and optimize resource allocation.
DESIGN, SETTING, AND PARTICIPANTS In this decision analytical model, age-specific and
stage-specific estimates of overall survival pre–COVID-19 were adjusted by the probability
of COVID-19 (individualized by county, treatment-specific variables, hospital exposure
frequency, and COVID-19 infectivity estimates), COVID-19 mortality (individualized by
age-specific, comorbidity-specific, and treatment-specific variables), and delay of cancer
treatment (impact and duration). These model estimates were integrated into a web
application (OncCOVID) to calculate estimates of the cumulative overall survival and
restricted mean survival time of patients who received immediate vs delayed cancer
treatment. Using currently available information about COVID-19, a susceptible-infected-
recovered model that accounted for the increased risk among patients at health care
treatment centers was developed. This model integrated the data on cancer mortality and
the consequences of treatment delay to aid treatment decisions. Age-specific and cancer
stage–specific estimates of overall survival pre–COVID-19 were extracted from the
Surveillance, Epidemiology, and End Results database for 691 854 individuals with 25 cancer
types who received cancer diagnoses in 2005 to 2006. Data from 5 436 896 individuals in
the National Cancer Database were used to estimate the independent impact of treatment
delay by cancer type and stage. In addition, data from 275 patients in a nested case-control
study were used to estimate the COVID-19 mortality rate by age group and number of
comorbidities. Data were analyzed from March 17 to May 21, 2020.
EXPOSURES COVID-19 and cancer.
MAIN OUTCOMES AND MEASURES Estimates of restricted mean survival time after the receipt
of immediate vs delayed cancer treatment.
RESULTS At the time of the study, the OncCOVID web application allowed for the selection of
up to 47 individualized variables to assess net survival for an individual patient with cancer.
Substantial heterogeneity was found regarding the association between delayed cancer
treatment and net survival among patients with a given cancer type and stage, and these 2
variables were insufficient to discriminate the net impact of immediate vs delayed treatment.
Individualized overall survival estimates were associated with patient age, number of
comorbidities, treatment received, and specific local community estimates of COVID-19 risk.
CONCLUSIONS AND RELEVANCE This decision analytical modeling study found that the
OncCOVID web-based application can quantitatively aid in the resource allocation of
individualized treatment for patients with cancer during the COVID-19 global pandemic.
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C ancer remains a leading cause of mortality, especiallyin high-income countries, with 607 000 cancer deathsin the US in 2019 alone and more than 9.5 million can-
cer deaths globally.1,2 However, the coronavirus disease
2019 (COVID-19) global pandemic, caused by the severe
acute respiratory syndrome coronavirus 2, has substantially
disrupted cancer care delivery.3 The pandemic has over-
whelmed many health care systems, and rapid policy changes
have been implemented to conserve resources. Cancer sur-
geries with curative intent during the peak of the pandemic
were often deemed elective and were reduced or canceled al-
together at various institutions.4 Systemic therapies and ra-
diotherapies have also been variably reduced to encourage
physical distancing and allow for staff redeployment. For cer-
tain cancers, a delay in the initiation of treatment may be safe5;
however, for most cancers, the data suggest that treatment de-
lay is associated with worse overall survival (OS).6
Further complicating matters, patients with cancer ap-
pear to be especially vulnerable to COVID-19.7 Patients with
cancer often have multiple comorbid conditions and risk fac-
tors, including older age, diabetes, hypertension, and cardio-
vascular disease, that are associated with an increase in the risk
of COVID-19–specific mortality.7-9 Thus, a careful and com-
plex balance is necessary to avoid unnecessary mortality in
patients with cancer. If such a balance were not optimized,
unnecessary cancer or COVID-19 deaths could reduce the net
success of the global pandemic response.
Countries and institutions have implemented systems to
triage and select patients for immediate vs delayed treat-
ment, most commonly through the use of a 3-tiered system.10-13
These tiered systems are inherently subjective, do not ac-
count for dynamic changes in COVID-19 risk, are unable to dis-
criminate patients with similar risk across cancer types, and
are unable to account for individualized COVID-19 mortality
risk. To our knowledge, there are no quantitative tools pres-
ently available to estimate the individualized risk of death for
a patient with cancer during the COVID-19 pandemic. We there-
fore sought to develop an integrated web-based survival model,
termed OncCOVID,14 to serve as a decision aid by providing per-
sonalized quantitative estimates of overall mortality for im-
mediate or delayed cancer treatment conditions.
Methods
Pre–COVID-19 Mortality
Data on patients with invasive cancer were extracted from
the Surveillance, Epidemiology, and End Results (SEER) da-
tabase of the National Cancer Institute. The SEER program
collects data from 28% of the US population via a network of
population-based incident tumor registries from geographi-
cally distinct regions. The SEER 18 registry15 (which includes
cases diagnosed from 2000 through the current data year) was
used, and all patients with an invasive cancer diagnosis from
2005 to 2006 were included. Patients with hematologic ma-
lignancies and patients with a cancer diagnosis via an au-
topsy or death certificate (<1.5% of patients) were excluded.
The years of diagnoses were chosen to be both representative
of contemporary patients with cancer who received diagno-
ses in the US and to enable the calculation of long-term sur-
vival estimates after diagnosis.
A total of 691 854 patients with up to 12 years of follow-up
met the eligibility criteria. Mortality codes in the SEER data-
base are assigned from death certificates that are completed
by the physician caring for the patient at the time of death.
From this data set, 25 cancer types were extracted. Other causes
of death were accounted for as competing events for cancer-
specific mortality modeling. For each cancer type, Cox pro-
portional hazards and Fine and Gray regression models were
used to estimate all-cause mortality and cancer-specific mor-
tality as a function of patient age and cancer stage.
Impact of Treatment Delay
Two approaches were used to provide an estimate of the im-
pact of treatment delay for survival. The first approach used
the National Cancer Database and included 5 436 896 pa-
tients who received cancer treatment between 2004 and 2014.
Time to any treatment from diagnosis was calculated for each
patient. Patients were excluded if their time to treatment was
missing or greater than 180 days after diagnosis, if their time
to death or last contact was missing, or if their clinical cancer
stage was missing. Stratified Cox proportional hazards mod-
els for each cancer type (with year of diagnosis as stratum) were
fit. In addition to clinical stage, the models included covari-
ates for race (White, Black, and other), rurality of treatment
facility (urban and rural), age group by decade (<50 years,
50-60 years, 61-70 years, 71-80 years, 81-90 years, and >90
years), insurance status, educational level, household in-
come, treatment facility type, treatment facility location, and
distance from patient’s residence to hospital. An institutional
review board waiver was obtained, and patient consent was
deemed not necessary to access publicly available datasets.
The second approach to assess the impact of treatment de-
lay for survival used a rapid semisystematic review of the pub-
lished literature. Four physicians (D.E.S., R.T.D., W.C.J., and
N.K.J.) conducted the review using MEDLINE via PubMed with
Key Points
Question What are the benefits and risks associated with delayed
treatment for an individual patient with cancer during the
coronavirus disease 2019 pandemic, and does the use of a
web-based survival model (OncCOVID) aid treatment decisions?
Findings In this decision analytical modeling study including data
from more than 6 million patients with cancer, the OncCOVID
model found heterogeneity regarding the impact of delayed
cancer treatment owing to patient and cancer factors that are not
currently captured by commonly used triage systems. Whether
delayed cancer treatment harms or improves expected survival
compared with immediate treatment is dependent on patient,
cancer, treatment, and community factors.
Meaning The study’s results indicate that the OncCOVID web
application may allow clinicians to estimate the net impact of
delayed cancer treatment for individual patients and to prioritize
patients for immediate treatment in settings with limited
treatment capacity.
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the search terms cancer type and treatment delay and sur-
vival. This review was performed for each of the 25 cancer types
included from the SEER database. Further details are avail-
able in eMethods in the Supplement.
Risk of COVID-19 Mortality
To estimate the risk of COVID-19 mortality, we estimated the
risk of infection with COVID-19 and the subsequent risk of mor-
tality if infected (ie, the case fatality rate [CFR]). The absolute
risk of COVID-19 mortality was calculated as the product of in-
fection probability and conditional mortality rate in patients
who were infected.
COVID-19 Risk Estimate
To estimate the risk of infection with COVID-19, a daily risk of
infection was calculated based on a susceptible-infected-
recovered model. For the present study, default values based
on the current literature and real-time data were used; how-
ever, all values in the model can be modified by the user as
needed. County-level data on the number of people who were
infected with COVID-19, recovered from COVID-19, and died
of COVID-19 were directly entered into the model from the
COVID-19 Case Tracker from Johns Hopkins University.16 The
US county population sizes were obtained from 2019 census
estimates.17 County population size was obtained for the county
in which the individual received cancer treatment and, if dif-
ferent, from the county in which the individual resided. The
web application allowed for global estimates, but the present
study focused only on US estimates.
The mean number of people infected per individual with
infection at the current time in the pandemic (ie, effective re-
production number [Rt]) and the mean duration of infectious-
ness were defaulted to published values (ie, Rt = 1; days of in-
fectiousness = 14) but can be user adjusted.18,19 Consistent with
reports of increased infection rates among health care
professionals,20-24 our model included a different estimated
risk of infection for individuals in health care settings. We as-
sumed a higher number of infectious contacts in health care
settings, which applied to both health care professionals and
patients receiving care that day. A higher infection risk was also
assumed for patients who received surgery as a component of
their treatment.25 Further details are available in eMethods in
the Supplement.
COVID-19 Mortality Risk Estimate
The CFRs were calculated using a combination of individual
patient-level data analysis from a recently reported study on
the impact of comorbidities for COVID-19 mortality26 and pub-
lished combined estimates of CFRs by age group.27 Initial es-
timates of CFRs were obtained from a penalized logistic re-
gression model, with age group by decade and number of
comorbidities as categorical covariates with no interaction
term. Comorbidities that have been associated to date with in-
creased COVID-19–specific mortality (cancer, diabetes, car-
diac disease, obesity, chronic kidney disease, hypertension, and
chronic obstructive pulmonary disease) were included.9,26,28
To obtain improved CFR estimates for each combination
of age and comorbidity count, the initial estimates were renor-
malized so that the weighted mean (across comorbidity counts)
for a given age group matched the values reported by the Novel
Coronavirus Pneumonia Emergency Response Epidemiology
Team27 while preserving the relative risk associated with the
increasing comorbidity counts reported by Gu et al.26 To es-
timate the prevalence of comorbidities in the US population,
the National Health and Nutrition Examination Survey, a na-
tionally representative survey of the noninstitutionalized ci-
vilian population, was used.30 We used data from the 2005 to
2006 cycle that was restricted to patients older than 40 years
who had complete information on age and sex and at least 1
nonmissing entry for the comorbidities we considered. This
process yielded a final sample of 3056 adults. Age-specific
prevalence values for the presence of 0 to 3 or more comor-
bidities were used to calculate weighted mean CFRs for each
age group. These estimated CFRs were also assumed to in-
crease for patients receiving chemotherapy as part of their can-
cer treatment or patients who were immunocompromised be-
fore receiving treatment based on published relative risk
estimates.29 Cumulative COVID-19 mortality rates over a speci-
fied period (with a default of 6 months) were calculated as the
cumulative probability of COVID-19 during this period multi-
plied by the individualized CFR.
Mortality and Survival Estimates
The estimates of COVID-19 specific mortality (M1(t)) and all-
cause pre-COVID-19 mortality (M2(t)) were combined to esti-
mate overall survival at time t as: S(t)=(1-M1(t))×(1-M2(t)).31 We
assumed that the risks of COVID-19 and non-COVID-19 mor-
tality were independent, conditional on the patient level co-
variates and that the COVID-19 mortality risk was 0 after 6
months.
Because of these competing causes of mortality, the as-
sumption of proportional hazards was not valid, and the es-
timated survival curves for immediate and delayed treat-
ment may have crossed. Thus, restricted mean survival time
(RMST) was chosen as a robust summary measure to charac-
terize the net impact of delaying cancer treatment.32 Re-
stricted mean survival time was interpreted as the mean sur-
vival time over a specified period and calculated as the area
under the OS curve. Unlike other commonly used measures,
such as OS at 5 years, RMST appropriately captured the dif-
ferential impact of COVID-19 mortality (which typically oc-
curs ≤2 months after infection) and cancer mortality (which
typically occurs >6 months after diagnosis). In the presented
analyses, RMST was calculated over 1 year or 5 years, as speci-
fied, with COVID-19 mortality estimated over a period of 6
months and assumed to be 0 thereafter. This last assumption
was based on the uncertainty associated with susceptible-
infected-recovered models that are performed for periods more
than 6 months in the future.
Statistical Analysis
Statistical analyses were conducted using R software, ver-
sion 3.6.2 (R Foundation for Statistical Computing). The web
application was developed using R Shiny (RStudio). Maps were
generated using the tmap, maptools, tmaptools, and sf pack-
ages for R software, and the penalized logistic regression analy-
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sis was conducted using the penalized package for R soft-
ware. Data were analyzed from March 17 to May 21, 2020.
Results
At the time of the study, the OncCOVID model allowed for the
selection of 47 inputs, 18 covariates (eg, age and comorbidi-
ties), and 29 parameter estimates (eg, hazard ratio [HR] for de-
lay of treatment) to characterize individual risk estimates for
those receiving immediate vs delayed cancer treatment
(Table 1).
Mortality
Across the 25 cancer types analyzed, substantial variability ex-
isted in cancer-specific and overall mortality (pre–COVID-19)
by cancer type and stage of disease (Figure 1). Five-year cancer-
specific mortality ranged from less than 1% to more than 80%
based on the cancer type and stage. The impact of delayed can-
cer treatment varied across cancer type and stage of disease.14
For example, treatment delays of up to 6 months were not as-
sociated with detrimental consequences for individuals with
stage II prostate cancer (HR, 1.000 per month of delay) in our
multivariable analysis. However, treatment delays were asso-
ciated with a substantial survival detriment among individu-
als with stage I, II, and III head and neck cancers (HR, 1.061-
1.161 per month of delay based on stage of disease).
The CFRs from COVID-19 are provided by age and num-
ber of comorbidities (in addition to cancer) in Table 2. These
estimates ranged from 0.4% for a patient aged 40 to 50 years
with no comorbid conditions beyond cancer to 39.3% for a
patient older than 80 years with 2 or more comorbid condi-
tions.
Integrated Overall Survival Estimates
The impact of delayed cancer treatment compared with im-
mediate treatment varied substantially across and within can-
cer types and stages (Figure 2A). This variation indicated that
individual hypothetical patients had large differences in the
harm or benefit associated with delayed treatment based on
Table 1. Inputs for OncCOVID Model
Category Default value Method
Patient age User defined NA
No. of comorbidities
0 Variable by age
Penalized logistic regression analysis normalized using data
from the Novel Coronavirus Pneumonia Emergency Response
Epidemiology Team (2020)26,27 and the NHANES30
1 Variable by age; RR ≈ 1.23
≥2 Variable by age; RR ≈ 2.30
Treatment
Chemotherapy Variable by age; RR ≈ 2.50 Estimated RR using data from Williams et al29
Surgerya,b RR = 5.73 Estimated RR using data from Wang et al20 and Zhang and
Cheng25
Hospital visits, No.a,b 3.47-fold increase per day Estimated increase in number of potentially infectious
contacts per day using data from Wang et al20
Duration of treatment
User defined User defined
Duration of treatment delay
Impact of treatment delay Variable by cancer type and stage Multivariable Cox proportional hazards model from the NCDB
Cancer
No. of types 25 Regression models using SEER data to estimate age-specific
CSM and OS by cancer type and stageStages I-IV
Infection riska
County-level estimates at residential location
Updated daily Estimated using data from the COVID-19 Case Tracker
16
and the US Census Bureau17County-level estimates at treatment center location
No. of people infected per individual with infection
at current time in pandemic
1 Time dependent; variable based on current state of
pandemic19
Duration of infectiousness, d 14 WHO18 estimates
Infection risk with immediate treatment
Variable Derived from other inputs using SIR model
Infection risk with delayed treatment
Health care system
Hospital system overwhelmed User defined User defined
Health care professionals on staff, %a 12.00 Estimated using data from the Kaiser Family Foundation33
Patients receiving health care per day, %a 0.23 CDC34 estimates
Patients receiving health care and surgery per day, %a 17.40 Estimated using data from Zhang and Cheng25 and the CDC34
Abbreviations: CDC, Centers for Disease Control and Prevention;
COVID-19, coronavirus disease 2019; CSM, cancer-specific mortality;
NA, not applicable; NCDB, National Cancer Database; NHANES, National Health
and Nutrition Examination Survey; OS, overall survival; RR, relative risk;
SEER, Surveillance, Epidemiology, and End Results; SIR, susceptible-infected-
recovered; WHO, World Health Organization.
a Risk of COVID-19, not COVID-19–specific mortality.
b Risk of contracting COVID-19 in excess of background risk (additional
potentially infectious contacts).
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patient age, cancer type, and cancer stage. This heteroge-
neity was also a complex function of age, the presence of co-
morbidities, the receipt of chemotherapy, and other vari-
ables in the model. For example, the estimated impact of
delayed treatment (relative to immediate treatment) in pa-
tients with prostate cancer was minimal, as these patients typi-
cally spend only 1 to 2 days in the hospital for surgery (with-
out receipt of chemotherapy) or receive 5 brief outpatient
treatments with stereotactic body radiotherapy (also without
receipt of chemotherapy). In contrast, among patients with
pancreatic cancer, the harm of treatment delay associated with
cancer-specific mortality exceeded any decrease in COVID-
19–specific mortality (Figure 2A).
Common 3-tiered methods were used to categorize pa-
tients with cancer into those who should receive immediate
treatment (tier 1 [eg, anal cancer]), those who could delay treat-
ment for a brief interval (tier 2 [eg, most cancer types]), and
those who could potentially delay treatment until the pan-
demic has resolved (tier 3 [eg, early-stage prostate cancer]).13
To illustrate the limitations of this method, the impact of treat-
ment delay across cancer types and stages was classified within
each tier (Figure 2B). The tiered system was unable to distin-
guish between patients who benefited the most from the re-
ceipt of immediate vs delayed cancer treatment.
Heterogeneity in the RMST difference between immedi-
ate vs delayed treatment was also found across geographic re-
gions based on current county-level COVID-19 case data and
population size. Figure 3 illustrates the spatial heterogeneity
across the US counties in a fixed scenario of a patient aged 70
years with stage 3 oropharyngeal cancer, diabetes, and hyper-
tension who will receive concurrent chemotherapy and radio-
therapy, with Rt fixed at 2.
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Estimated impact of 3-month treatment delay for restricted mean survival time (RMST) for varying patient factors (eg, age and comorbidities), disease
characteristics (eg, cancer type and stage), treatment characteristics (eg, chemotherapy and number of days in hospital), and community factors (eg, effective
reproduction number [Rt]). A, Estimated difference in 5-year RMST for immediate vs delayed treatment by cancer type. B, Estimated difference in 5-year RMST
for immediate vs delayed treatment by tier.
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Discussion
Decisions are currently being made to triage cancer treat-
ment based on qualitative methods for categorizing patients
with cancer.3,10-12,35 These methods are primarily imple-
mented based on perceived urgency, tumor site, and cancer
stage and do not account for patient-level factors that impact
the risk of COVID-19 mortality (eg, age, comorbidities, loca-
tion, and treatment) and thus do not provide personalized
treatment guidelines. As we indicated, there is potential for
net harm associated with immediate or delayed treatment
within a given cancer type and stage owing to the complexity
of variables that impact each patient’s risk. Our model aims to
improve current recommendations and provides quantita-
tive estimates to optimize the outcomes of patients with can-
cer during the global pandemic.
Our model illustrates the challenges of decision-making
during the pandemic. An illustrative patient (categorized as
tier 2) was a woman aged 70 years from New York City (dur-
ing the peak of the first wave of the pandemic) who had
hypertension and diabetes and a diagnosis of stage II triple-
negative breast cancer, for which a standard of care option is
breast conservation surgery, chemotherapy, and adjuvant
radiotherapy. Compared with a 3-month delay, our model
estimated that immediate treatment was associated with an
8% worse 5-year OS or a 5-year RMST decrease of 165 days.
In contrast, a patient aged 40 years with no comorbidities
and the same stage II breast cancer diagnosis living in
Washtenaw County, Michigan, would have a less than 0.1%
estimated difference in 5-year OS between immediate and
delayed treatment.
Our model is focused on the impact of these decisions for
an individual patient rather than the impact for the popula-
tion or society as a whole. Each day, health care professionals
are tasked with either explaining to their patients the safety
of delaying cancer treatment or advocating for their patients
to receive treatment during the pandemic despite the risks of
COVID-19. Our model can also aid in the institutional triage of
patients with cancer. Every hospital has a fixed capacity to treat
patients with cancer during a given day, and many centers have
delayed hundreds to thousands of cancer treatments.36 Thus,
rather than relying on a simple tiered method to evaluate which
patients should immediately receive treatment, one could use
a model like OncCOVID to more accurately identify which pa-
tients will experience the most benefit from immediate treat-
ment and quantitatively estimate the benefits and harms across
the population with cancer at a given institution. One could
more confidently make institutional policy decisions regard-
ing thresholds for treatment among patients who are likely to
experience the greatest net benefit.
Limitations
This study has several limitations. Like all modeling studies,
it relies on multiple assumptions. The estimates used in our
model are based on currently available data, which are rap-
idly reported and refined from around the world. Not all pa-
tients with COVID-19 are tested, and the extent to which re-
ported case counts are underestimations likely varies between
states and over time. In addition, recovered cases are not cur-
rently tracked and reported rigorously; however, at this point
in the pandemic, this factor has few implications for the model
estimates. It is also currently unknown to what extent social
distancing impacts model parameters. Many estimates, such









Heat map was based on county-level
infection estimates on April 17, 2020,
for a patient aged 70 years with stage
3 oropharyngeal cancer, diabetes,
and hypertension, who will receive
concurrent chemotherapy and
radiotherapy. The effective
reproduction number (Rt) was set at
2 to calculate the 5-year difference in
restricted mean survival time (RMST;
calculated as immediate treatment
minus delayed treatment conditions)
using a 1-month delay.
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as the impact of the delay of cancer treatment for cancer-
specific survival, have their own limitations and potential
sources of bias despite the use of multivariable modeling.
There are numerous types and combinations of chemo-
therapy used clinically; however, in our model, they were treated
as 1 binary variable that was age dependent. It is probable that
different regimens will have a different impact for COVID-19
mortality; however, these granular data are not yet available.
In addition, precise estimates of the cumulative consequences
of combining multiple variables that have been reported to im-
pact COVID-19 or COVID-19–specific mortality risk (eg, the receipt
of chemotherapy and the presence of specific comorbidities) are
unknown. To address these unknown variables, we have made
all inputs adjustable by the user, and we are conducting multiple
ongoing parallel projects in an attempt to provide more reliable
cancer type and stage–specific estimates.
The impact of comorbidities for cancer-specific survival
and other-cause mortality (other than COVID-19) has not been
incorporated into the model at this time. The current version
of the model is designed to evaluate the net impact of a delay
in all components of cancer therapy from the time of diagno-
sis; thus, HR estimates for the impact of only 1 component of
therapy (ie, the patient had surgery and is considering a delay
in receiving adjuvant breast radiotherapy) are not incorpo-
rated into the model. Although the 2005 to 2006 SEER co-
hort was selected to have 10 years of follow-up, advances in
treatment have occurred that may produce small changes in
the 5-year survival estimates that were unaccounted for in our
models. However, the user can readily adjust all survival es-
timates as needed. Any model would ideally have indepen-
dent validation. Although statistically and methodologically
desirable, there are no data sets containing 5-year outcomes
for patients with COVID-19, and we will continue to work with
multiple ongoing prospective COVID-19 registries.
In addition, the study has multiple limitations owing to
the unknown factors of COVID-19. For instance, the long-
term health consequences of COVID-19 are unknown among
patients who survive the infection. There may also be sud-
den and unforeseeable changes in policy at either the hospi-
tal, community, state, or federal level that could be associ-
ated with infection rates and the ability to treat patients with
cancer. The OncCOVID application is flexible and fully
adjustable by the user, which allows for alteration of any
adjustments made. An updated version, which incorporates
multiple refined models of cancer-specific survival, hazard
estimates of treatment delay, estimates of geographically
personalized Rt, and other ongoing upgrades, is being devel-
oped based on newly available data. Confidence intervals for
the outputs were not provided at this time given the statisti-
cal challenges in capturing variance estimates across mul-
tiple levels of analysis. Thus, caution is warranted when
interpreting model estimate differences as statistically sig-
nificant or clinically meaningful.
Conclusions
We have developed a resource to assist in the personaliza-
tion and timing of cancer care during the COVID-19 pan-
demic. Although it is understandable that patients and
health care professionals may experience anxiety about
delays in cancer treatment, in many circumstances, a delay
in treatment may provide a net benefit or minimal net harm
to the individual. However, it may be prudent for organiza-
tions and institutions to recognize that many patients with
cancer could be substantially harmed from cancer treatment
delays and that the benefit to the individual may need to be
balanced with that of the population.
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